Rolle des Rezeptors für Hyaluronsäure-vermittelte Motilität RHAMM/CD168 bei der Proliferation myeloischer Blasten
Dissertation
Autoren
Schönsteiner, Dorothée
Fakultäten
Medizinische FakultätZusammenfassung
RHAMM, the receptor for hyaluronic acid mediated motility (CD168) was identified as leukemia associated and tumor associated antigen. In normal tissues RHAMM is not represented significantly.
This declares RHAMM to an interesting target in therapy of myeloid neoplasms. The cell line K562 was in the focus of the studies.
Nucleofection of small interfering ribonucleic acid (siRNA) against RHAMM led to an effective inhibition of the expression of RHAMM. Using realtime PCR, a reduction to 30 % of the expression after 72 h could be detected.
At the same time analyses about growth and vitality of cells after nucleofection with siRNA showed an inhibition of cell growth.
Summary: Nucleofection with siRNA is an effective method to reduce gene activity. Due to the biological characteristics, the effect is not permanent.
Erstellung / Fertigstellung
2011
Normierte Schlagwörter
Akute myeloische Leukämie [GND]RNS-Interferenz [GND]
K562 cells [MeSH]
Leukemia, myeloid acute [MeSH]
Schlagwörter
K562; Nukleofektion; RHAMM; siRNADDC-Sachgruppe
DDC 610 / Medicine & healthMetadata
Zur LanganzeigeZitiervorlage
Schönsteiner, Dorothée (2012): Rolle des Rezeptors für Hyaluronsäure-vermittelte Motilität RHAMM/CD168 bei der Proliferation myeloischer Blasten. Open Access Repositorium der Universität Ulm. Dissertation. http://dx.doi.org/10.18725/OPARU-2319